Susan M. Chang, MD

Susan M. Chang, MD

Professor in Residence, Department of Neurological Surgery, UCSF
Lai Wan Kan Endowed Chair, UCSF

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

My research interest is in the development of novel therapies for patients with brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients. I am the principal investigator and co-investigator on more than 15 active clinical trials that evaluate the wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and serve on the coordinating committee for that entity. I have served as a member of the Board of Scientific Directors and currently am a member of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the Helen Diller Family Comprehensive Cancer Center. I am the PI of a P01 grant related to integrating advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). For the UCSF Brain Tumor SPORE, I am the clinical co-PI of the overall grant, a member of the Executive Committee, the co-Director of the Biostatistical and Clinical Core and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.


University of British Columbia, 1981
University of British Columbia, MD, 1985, Medicine
Pasqua Hospital, University of Saskatchewan, Regina, Internship, 1985-1986
Plains Health Centre, Regina, Saskatchewan, Residency, 1986-1987
Toronto General Hospital, U of Toronto, Ontario, Residency, 1987-1989
Princess Margaret Hospital, U of Toronto, Ontario, Residency, 1989-1991
Royal College of Physicians & Surgeons, Canada, FRCPS, 1990, Internal Medicine
Royal College of Physicians & Surgeons, Canada, FRCPS, 1991, Medical Oncology

Professional Experience

  • 1991-1992
    Lecturer, Department of Medicine, University of Toronto, Ontario
  • 1991-1992
    Director of Palliative Care, Department of Medicine, St Michael's Hospital, Toronto, Ontario
  • 1992-1994
    Clinical Instructor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-1996
    Assistant Clinical Professor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-present
    Member, Brain Tumor Research Center, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1996-1998
    Assistant Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1998-2004
    Associate Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2003-present
    Vice Chair of Clinical Enterprise, Department of Neurological Surgery, UCSF
  • 2004-present
    Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2005-present
    Director, Division of Neuro-Oncology, Department of Neurological Surgery, UCSF
  • 2013-present
    Director, Gordon Murray Neuro-Oncology Caregiver Program
  • 2014-present
    Editor in Chief of Neuro-Oncology Practice
  • 2015-present
    Program Leader, Neuro-Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 2014
    UCSF Voice of the Patient Pinnacle Award x 7 years, Press Ganey award for excellence in patient care per division, Hall of Fame
  • 2014
    John J. Mealey Jr. Neuro-Oncology Lectureship

Selected Publications

  1. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015 Dec 4.
    View on PubMed
  2. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55.
    View on PubMed
  3. Replicating Patient-Specific Severe Aortic Valve Stenosis With Functional 3D Modeling. Circ Cardiovasc Imaging. 2015 Oct; 8(10).
    View on PubMed
  4. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell. 2015 Sep 14; 28(3):307-17.
    View on PubMed
  5. Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T. Neuroimage Clin. 2015; 9:291-9.
    View on PubMed
  6. Diagnosis of ischemia in hypertrophic cardiomyopathy: role of computed tomography and nuclear stress testing. Curr Opin Cardiol. 2015 Sep; 30(5):483-92.
    View on PubMed
  7. Association of Left Ventricular Diastolic Dysfunction with Subclinical Coronary Atherosclerotic Disease Burden Using Coronary Artery Calcium Scoring. J Atheroscler Thromb. 2015 Dec 1; 22(12):1278-86.
    View on PubMed
  8. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  9. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  10. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma†. Neuro Oncol. 2016 Jan; 18(1):87-95.
    View on PubMed
  11. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25; 372(26):2499-508.
    View on PubMed
  12. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8.
    View on PubMed
  13. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015 May 29; 348(6238):1036-9.
    View on PubMed
  14. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
    View on PubMed
  15. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015 Apr; 129(4):597-607.
    View on PubMed
  16. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361.
    View on PubMed
  17. Value of CACS Compared With ETT and Myocardial Perfusion Imaging for Predicting Long-Term Cardiac Outcome in Asymptomatic and Symptomatic Patients at Low Risk for Coronary Disease: Clinical Implications in a Multimodality Imaging World. JACC Cardiovasc Imaging. 2015 Feb; 8(2):134-44.
    View on PubMed
  18. Simultaneous imaging of radiation-induced cerebral microbleeds, arteries and veins, using a multiple gradient echo sequence at 7 Tesla. J Magn Reson Imaging. 2015 Aug; 42(2):269-79.
    View on PubMed
  19. MDCT Assessment of Mechanical Circulatory Support Device Complications. JACC Cardiovasc Imaging. 2015 Jan; 8(1):100-2.
    View on PubMed
  20. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015 Jan; 121(2):331-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI